Kymanox® Announces Evan Edwards as President

Morrisville, North Carolina USA, May 08, 2024 (GLOBE NEWSWIRE) — Kymanox®, a leading provider of product development, engineering, quality, regulatory and technical solutions serving exclusively the life sciences industry, is pleased to announce that Evan Edwards has been promoted to President. This organizational change allows Kymanox to amplify the customer experience and further benefit from Evan’s expertise in innovation and leadership. The move provides increased focus on Kymanox’s operational processes and allows Stephen M. Perry, CEO and Founder, to focus on longer-term strategic initiatives and transformative business partnerships.

Evan brings deep experience and expertise to his new role, having held leadership roles at Kymanox over the past four years, most recently as Director of Innovation and also in the life sciences industry for more than two decades. He is a recognized leader and inventor with a track record of growth, commercialization and innovation in translational medicine.

“We are thrilled to elevate Evan to President of Kymanox,” Perry said. “His experience and continued leadership will be invaluable as we continue to professionalize and evolve our unique platform.” We are poised for growth both across market segments and geographies – and this evolution of leadership allows the company to remain agile, which is critically important for any business. “.

As President, Evan will be responsible for overseeing the company’s short-term operations and driving strategic growth initiatives. He will work closely with the rest of the Kymanox management team and other leadership groups within the organization, to ensure that Kymanox continues to deliver exceptional value to its customers and to support the CEO in long-term strategic planning and market positioning – all to ultimately benefit the patients who need it.

“I am honored to serve the Kymanox team as president,” said Evan. “I look forward to working with our talented team to continue to provide innovative solutions to our customers, supporting them in pursuing regulatory approval and commercialization of their products, and to generating continued growth opportunities for the company.

About Kymanox®:
Kymanox provides proven, end-to-end collaborative solutions that help bring life sciences products to market – and keep them there. We are a global professional services organization that supports comprehensive drug development with integrated science, engineering, compliance (e.g., QA/RA), and technical project management. Our work in small and large molecules, medical devices and combination products gives us a very unique advantage. Through our diverse team of experts, Kymanox helps customers address commercialization challenges that arise throughout a product’s lifecycle – from early development to post-market – with safety, quality, optimized efficiency and accessibility. We strive to advance life sciences innovation through meaningful solutions and collaboration…because patients deserve better. Kymanox was founded in 2004 and is headquartered in Morrisville, North Carolina, United States. Kymanox is backed by WestView Capital Partners, a Boston-based growth equity firm. For more information, visit http://www.kymanox.com/.